Description

Annual Reports in Medicinal Chemistry provides timely and critical reviews of important topics in medicinal chemistry together with an emphasis on emerging topics in the biological sciences, which are expected to provide the basis for entirely new future therapies. Sections I-IV are disease orientated and generally report on specific medicinal agents. Sections V and VI continue to emphasize important topics in medicinal chemistry, biology, and drug design. Section VII looks at Trends and Perspectives in the pharmaceuticals market.

Key Features

* Critical reviews of the previous year's literature in many topics of interest to medicinal chemists * Highlights major developments in medicinal chemistry * Includes a comprehensive set of cumulative indices to easily locate topics in all published volumes

Readership

For medicinal, pharmaceutical and organic chemists

Table of Contents

I. CENTRAL NERVOUS SYSTEM DISEASES
1. Neuronal Nicotinic Acetylcholine Receptor Modulators: Recent Advances and Therapeutic Potential (S.R. Breining et al.).
2. Recent Advances in Selective Serotonergic Agents (W.E. Childers, Jr., A.J. Robichaud).
3. BACE Inhibitors for the Treatment of Alzheimer’s Disease (E.W. Baxter, A.B. Reitz).
4. Positron Emission Tomography Agents for Central Nervous System Drug Development Applications (N. Scott Mason, C. Mathis).

II. CARDIOVASCULAR AND METABOLIC DISEASES
5. Emerging Topics in Atherosclerosis HDL Raising Therapies (P.J. Sinclair).
6. Small Molecule Anticoagulant/Antithrombotic Agents (R.M. Scarborough et al.).
7. CB1 Cannabinoid Receptor Antagonists (F. Barth).
8. Melanin-Concentrating Hormone as a Therapeutic Target (M.D. McBriar, T.J. Kowalski).
9. Glycogen Synthase Kinase-3 (GSK-3): A Kinase with Exceptional Therapeutic Potential (J.W. Benbow et al.).
10. Inhibitors of Dipeptidyl Peptidase 4 as Therapeutic Agents (S.L. Gwaltney II, J.A. Stafford).
11. Recent Advances in Therapeutic Approaches to Type 2 Diabetes (R. Sarabu, J. Tilley).

III. INFLAMMATORY, PULMONARY, AND GASTROINTESTINAL DISEASES
12. The TRPV1 Vanilloid Receptor: A Target for Therapeutic Intervention (J. Guy Breitenbucher et al.).
13. Leukotriene Biosynthesis Inhibitors (R.W. Friesena, D. Riendeaub).
14. CXCR3 Antagonists (J.C. Medina et al.).

Details

No. of pages:
558
Language:
English
Copyright:
© 2005
Published:
Imprint:
Academic Press
Print ISBN:
9780120405404
Electronic ISBN:
9780080458175

About the editor

Annette Doherty

Affiliations and Expertise

Pfizer Global R&D, Sandwich Laboratories, United Kingdom